• Indexing List

IP Indian Journal of Immunology and Respiratory Medicine

Delamanid- A ray of hope for drug resistant tuberculosis

Full Text PDF Share on Facebook Share on Twitter

Author Details: Mohammad Atif, Mohd Maroof, Sankalp Yadav

Volume : 2

Issue : 3

Online ISSN : 2581-4222

Print ISSN : 2581-4214

Article First Page : 66

Article End Page : 68


The emergence of drug-resistant tuberculosis is a major threat to tuberculosis care and control throughout the world. The lack of effective, affordable and safe drugs for the treatment of MDR-TB is a key factor in the inability of programs to boost up their treatment efforts to meet national and global targets. Delamanid, a newer mycobacterial cell wall synthesis inhibiting drug, received a conditional approval from European medicines agency for the treatment of MDR-TB. Delamanid, in addition to its previously demonstrated efficacy in pulmonary tuberculosis, might be an effective therapeutic approach to treating extra pulmonary tuberculosis. Treatment with Delamanid for 6 months in combination with an optimized regimen can improve patient outcomes and reduce mortality and morbidity among patients with both multidrug-resistant (MDR) and extensively drug-resistant TB (XDR).

: Delamanid; Efficacy; MDR-TB; Tuberculosis